Cagrilintide + Semaglutide

What It Is

Cagrilintide + Semaglutide is a fixed-dose combination of two peptide drugs being developed (not yet fully approved by regulators) for weight management and type 2 diabetes. In clinical development by Novo Nordisk, this combination has been given the investigational name CagriSema.

• Semaglutide: A synthetic peptide that mimics the hormone glucagon-like peptide-1 (GLP-1). It stimulates insulin release, reduces glucagon secretion, slows gastric emptying, and suppresses appetite. Semaglutide is already approved in several formulations for type 2 diabetes and chronic weight management.

• Cagrilintide: A long-acting synthetic analogue of amylin (a hormone co-secreted with insulin). It activates amylin and calcitonin receptors to enhance satiety (feeling full) and slow gastric emptying, acting through pathways different from GLP-1.

 How the Combination Works

The idea behind this peptide duo is synergy—each component targets distinct hormonal pathways involved in appetite and metabolism:

• Semaglutide acts on GLP-1 receptors in the brain and gut to reduce hunger, improve blood sugar control, and delay how quickly food leaves the stomach.

• Cagrilintide engages amylin and calcitonin receptors, enhancing feelings of fullness and further slowing gastric emptying through a complementary neural route.

Together, these actions can lead to greater appetite suppression and more substantial weight loss than either molecule alone because multiple appetite- and metabolism-regulating systems are engaged simultaneously.